Registration successful.
Account activated – Pending validation
Your account has been activated successfully, but we still need to validate you as a UK healthcare professional. We’ll send you an email with the result. Please note this could take up to 10 days.
In the meantime, you can enjoy access to all the latest news, events and resources on our website.
Ellipta device
Time to teach and ease of use for the Ellipta device
COPD management: where could you intervene to reduce the burden of COPD?
Trelegy Ellipta (fluticasone furoate / umeclidinium / vilanterol) is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid (ICS) and a long-acting β2-agonist (LABA) or a combination of a LABA and a long-acting muscarinic antagonist (LAMA).1
Patients learn to use the Ellipta device faster than an MDI, making intervention simple for every Healthcare Professional (p<0.001)7
Other inhaler types: Accuhaler, MDI, Turbohaler, HandiHaler and Breezhaler. Randomised open label, single visit, placebo inhaler, crossover comparison in patients naÏve to Ellipta and the comparator inhalers. N=567. Time to teach based on reading the PIL followed by nurse instruction if required.
Nearly half of patients do not survive five years after their first COPD hospitalisation. Stepping up to triple therapy with Trelegy Ellipta could help stabilise COPD over time and improve patient outcomes.8
median survival of 3.6 years, cohort of 73 106 patients during 17-year follow-up
Case Study: COPD Management in Practice
See how Beverley Bostock approaches COPD care to support improved patient outcomes.
COPD exacerbations
Professor Richard Russel talks about the challenges faced by patients with COPD
Access clinical evidence and practical guidance for appropriate patients
Resources to support ongoing COPD management
References:
- Trelegy Ellipta Summary of Product Characteristics.
- Hurst JR et al. N Engl J Med;2010;363:1128-1138.
- Ramon MA, et al. Eur Respir J 2018;52;1800079.
- Han MK et al. Adv Ther;2024;41;3977–3981.
- GOLD. Global Strategy for the Diagnosis, Management and Prevention of COPD. 2026 Report
- Riley JH, et al 2016;11;1873-1880.
- Van der Palen J et al, NPJ Prim Care Respir Med 2016;26:16079.
- Suissa S, et al. Thorax 2012; 67(11):957–963.
CI, confidence interval; ICS, inhaled corticosteroid; LABA, long-acting β2-agonist; LAMA, long-acting muscarinic antagonist; MDI, metered dose inhaler; PIL, patient information leaflet
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to GSK on 0800 221 441 or UKSafety@gsk.com.
September 2026 | PM-GB-FVU-WCNT-260008 (V1.0)
